deferiprone has been researched along with Parkinson Disease, Secondary in 2 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Y | 1 |
| Pham, AN | 1 |
| Waite, TD | 1 |
| Workman, DG | 1 |
| Tsatsanis, A | 1 |
| Lewis, FW | 1 |
| Boyle, JP | 1 |
| Mousadoust, M | 1 |
| Hettiarachchi, NT | 1 |
| Hunter, M | 1 |
| Peers, CS | 1 |
| Tétard, D | 1 |
| Duce, JA | 1 |
2 other studies available for deferiprone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.
Topics: Animals; Deferiprone; Disease Models, Animal; Dopamine; Iron; Iron Chelating Agents; Oxidative Stres | 2018 |
Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators.
Topics: Cell Line; Crystallography, X-Ray; Deferiprone; Humans; Iron Chelating Agents; Models, Molecular; Ne | 2015 |